Remove 2017 Remove Leads Remove Safety
article thumbnail

RWE shows efficacy of nirsevimab for infant RSV

European Pharmaceutical Review

HARMONIE investigated the efficacy and safety of a single intramuscular dose of nirsevimab. Agreed in March 2017, AstraZeneca leads development and manufacturing activities, and Sanofi leads commercialisation activities. HARMONIE compared nirsevimab treatment to no intervention (standard of care).

Safety 104
article thumbnail

Developing the EU’s first intestinal microbiota-based biologic

European Pharmaceutical Review

The main objective was to evaluate the efficacy and safety of MBK-01 compared to fidaxomicin, providing significant insights into the potential of MBK-01 as a treatment for primary or recurrent CDI and contributing to the advancement of microbiome-based therapies. 2017; 55(7):1998-2008. Clin Microbiol Infect. 2021; 27 (2): S1-S21.

Safety 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

He leads the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital in Boston. Meanwhile, the top 25 pharmaceutical companies reported a “healthy average operating margin of 22 percent” at the end of 2017, according to an analysis by GlobalData.

Pharma 255
article thumbnail

QT Medical® Announces Completion of Series B Financing of $12 Million

Legacy MEDSearch

Its flagship product, the Personal Cardiac Assistant (PCA 500) , is the only hospital-grade, resting 12-lead ECG device cleared by the FDA and CE marked for both professional and patient use. Resting 12-lead ECG is the most used medical test for screening, diagnosing, and monitoring heart disease.

Medical 52
article thumbnail

How automation can help to address supply chain challenges in pharma

pharmaphorum

Supply chain challenges take many forms in pharma – from capacity issues, to managing excess safety stock, and ensuring accurate supplier communication. These shocks can lead to unpredictable or even absent shipments, meaning drug production labs often aren’t dealing with a stable and regular volume of raw materials.

Pharma 103
article thumbnail

SparingVision raises €75m for eye disease gene therapies

pharmaphorum

SparingVision’s lead candidates are both targeting inherited retinal diseases (IRDs), a group which already has a gene therapy on the market in Novartis’ Luxturna (voretigene neparvovec), which was approved by the FDA in 2017 for biallelic RPE65 mutation-associated retinal dystrophy, a group which includes a small group of RP patients.

Safety 52
article thumbnail

Three-dose vaccine prevents HIV patients getting hepatitis B

European Pharmaceutical Review

At week 28, the study assessed the vaccine’s safety and levels of anti-HBV surface antibodies (HBsAbs). A two-dose version of the vaccine was approved by the US Food and Drug Administration (FDA) in 2017. It causes severe hepatitis B infection that can lead to progressive liver disease.